full year results 2017: tables - roche - doing now what ...29d4dcde-3b4d-43e3-91d6-08fdbd951… ·...

1

Appendix: Tables

1. Sales January to December 2017 and 2016....................................................................................................................................................................................................... 2

2. Quarterly sales and constant exchange rate sales growth by Division in 2017 and 2016................................................................................................................................. 3

3. Pharmaceuticals Division – Top-selling pharmaceuticals and recent new launches ......................................................................................................................................... 4

4. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD December 2017 vs. YTD December 2016 .............................................................. 5

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth .............................................................................................. 6

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States ....................................................................... 7

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe ................................................................................. 8

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan .................................................................................... 9

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International* .................................................................... 10

10. Roche Group consolidated income statement for the twelve months ended 31 December 2017 ................................................................................................................ 11

11. Roche Group core results reconciliation – Full Year 2017 ............................................................................................................................................................................... 12

12. Divisional core results reconciliation – Full Year 2017 .................................................................................................................................................................................... 13

13. Roche Group consolidated balance sheet ....................................................................................................................................................................................................... 14

14. Roche Group consolidated statement of cash flows ....................................................................................................................................................................................... 15

2

1. Sales January to December 2017 and 2016

Twelve months ended % change

CHF millions 31 December

2017 2016 At CER In CHF

Pharmaceuticals Division 41,220 39,103 5 5

United States 20,496 18,594 10 10

Europe 9,051 9,159 -2 -1

Japan 3,713 3,711 3 0

International* 7,960 7,639 4 4

Diagnostics Division 12,079 11,473 5 5

Roche Group 53,299 50,576 5 5

* Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

3

2. Quarterly sales and constant exchange rate sales growth by Division in 2017 and 2016

CHF millions

% change % change % change % change % change

Q4 2016 vs. Q1 2017 vs. Q2 2017 vs. Q3 2017 vs. Q4 2017 vs.

Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016

Pharmaceuticals Division 9,963 3 10,177 3 10,344 7 10,115 6 10,584 6

United States 4,744 3 5,070 6 5,115 10 5,081 12 5,230 12

Europe 2,243 2 2,273 1 2,266 0 2,227 -5 2,285 -5

Japan 1,021 3 856 -2 915 2 904 6 1,038 6

International* 1,955 3 1,978 1 2,048 8 1,903 2 2,031 3

Diagnostics Division 3,108 5 2,765 6 3,058 4 2,975 6 3,281 4

Roche Group 13,071 3 12,942 4 13,402 6 13,090 6 13,865 5

*Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

4

3. Pharmaceuticals Division – Top-selling pharmaceuticals and recent new launches

Top-selling pharmaceuticals

and recent new launches Total United States Europe Japan International*

January – December 2017 CHF m % CHF m % CHF m % CHF m % CHF m %

MabThera/Rituxan 7,388 1 4,133 6 1,690 -11 293 4 1,272 4

Herceptin 7,014 3 2,697 8 2,123 2 295 -2 1,899 -1

Avastin 6,688 -2 2,894 -2 1,776 -5 817 1 1,201 5

Perjeta 2,196 19 1,013 12 767 21 120 15 296 42

Actemra/RoActemra 1,926 14 756 17 631 12 304 10 235 12

Xolair 1,742 16 1,742 16 - - - - - -

Lucentis 1,414 1 1,414 1 - - - - - -

Activase/TNKase 1,219 10 1,168 10 - - - - 51 8

Kadcyla 914 10 343 9 347 4 70 -3 154 43

Esbriet 869 13 640 13 190 5 - - 39 95

Recent new launches

Esbriet 869 13 640 13 190 5 - - 39 95

Tecentriq 487 209 456 196 17 ** - - 14 **

Ocrevus 869 - 860 - 4 - - - 5 -

Alecensa 362 101 173 136 26 ** 147 41 16 -

Gazyva 278 41 158 36 80 49 - - 40 43

Cotellic 60 30 16 19 35 14 - - 9 **

Hemlibra 3 - 3 - - - - - - -

* Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others ** Over 500%

5

4. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD December 2017 vs. YTD December 2016

CHF millions

Total United States Europe Japan International*

CHF m % CHF m % CHF m % CHF m % CHF m %

MabThera/Rituxan 7,388 1 4,133 6 1,690 -11 293 4 1,272 4

Herceptin 7,014 3 2,697 8 2,123 2 295 -2 1,899 -1

Avastin 6,688 -2 2,894 -2 1,776 -5 817 1 1,201 5

Perjeta 2,196 19 1,013 12 767 21 120 15 296 42

Actemra/RoActemra 1,926 14 756 17 631 12 304 10 235 12

Xolair 1,742 16 1,742 16 - - - - - -

Lucentis 1,414 1 1,414 1 - - - - - -

Activase/TNKase 1,219 10 1,168 10 - - - - 51 8

Kadcyla 914 10 343 9 347 4 70 -3 154 43

Esbriet 869 13 640 13 190 5 - - 39 95

Ocrevus 869 - 860 - 4 - - - 5 -

Tarceva 843 -18 457 -18 140 -21 92 -9 154 -18

Pulmozyme 730 6 506 7 124 2 - - 100 10

CellCept 697 -6 120 -30 178 -1 78 13 321 1

Tamiflu 535 -33 239 -49 27 -74 148 25 121 13

Mircera 505 -1 - - 84 -5 210 -1 211 1

Tecentriq 487 209 456 196 17 ** - - 14 **

Xeloda 453 -10 36 -55 26 -19 107 -1 284 0

Alecensa 362 101 173 136 26 ** 147 41 16 -

Madopar 334 13 - - 103 3 16 -1 215 20

* Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others ** Over 500%

6

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions



Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016

MabThera/Rituxan 1,816 2 1,899 4 1,938 3 1,783 1 1,768 -3

Herceptin 1,657 0 1,756 2 1,786 4 1,691 0 1,781 6

Avastin 1,669 -4 1,684 -2 1,721 0 1,592 -4 1,691 1

Perjeta 467 14 524 19 541 16 552 17 579 22

Actemra/RoActemra 450 14 445 15 477 12 485 13 519 14

Xolair 378 8 437 22 429 13 448 17 428 15

Lucentis 329 -14 392 9 335 -5 399 8 288 -11

Activase/TNKase 301 15 316 13 297 12 307 15 299 0

Kadcyla 215 2 222 11 221 7 228 10 243 12

Esbriet 197 10 202 13 216 19 219 3 232 17

Ocrevus - - - - 192 - 308 - 369 -

Tarceva 259 -11 211 -19 225 -15 202 -16 205 -21

Pulmozyme 181 1 175 9 177 -1 179 8 199 10

CellCept 182 -10 170 -10 176 -4 169 -8 182 -1

Tamiflu 291 72 270 -27 94 110 33 -61 138 -52

Mircera 137 23 115 -4 121 -2 128 -2 141 3

Tecentriq 80 - 113 - 124 * 118 104 132 65

Xeloda 156 18 104 -7 125 5 112 -4 112 -28

Alecensa 60 -15 68 124 80 88 96 100 118 99

Madopar 76 6 86 18 77 10 81 10 90 14

* Over 500%

7

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions



Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016

MabThera/Rituxan 978 3 1,045 6 1,074 3 997 9 1,017 6

Herceptin 611 1 680 3 694 8 627 3 696 16

Avastin 703 -10 765 -2 751 -3 677 -5 701 1

Perjeta 222 1 257 14 250 7 249 10 257 18


Xolair 378 8 437 22 429 13 448 17 428 15

Lucentis 329 -14 392 9 335 -5 399 8 288 -11

Activase/TNKase 289 16 305 14 285 12 293 15 285 0

Kadcyla 78 -2 89 11 82 2 83 7 89 15

Esbriet 150 19 153 19 161 20 162 3 164 11

Ocrevus - - - - 191 - 306 - 363 -

Tarceva 148 -8 109 -21 121 -15 117 -13 110 -24

Pulmozyme 125 -4 125 10 124 2 120 4 137 11

CellCept 38 -31 33 -26 34 -23 27 -41 26 -29

Tamiflu 141 16 156 -39 32 125 9 -83 42 -70

Mircera - - - - - - - - - -

Tecentriq 78 - 109 - 120 * 112 99 115 48

Xeloda 52 312 6 30 21 68 6 -38 3 -94

Alecensa 26 * 36 244 37 137 45 113 55 112

Madopar - - - - - - - - - -

* Over 500%

8

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions



Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016

MabThera/Rituxan 450 -1 465 1 458 -3 406 -16 361 -26

Herceptin 486 -2 522 3 525 2 524 -2 552 6

Avastin 439 -4 446 -3 435 -7 438 -8 457 -3

Perjeta 155 22 176 21 190 21 201 20 200 21


Xolair - - - - - - - - - -

Lucentis - - - - - - - - - -

Activase/TNKase - - - - - - - - - -

Kadcyla 81 -6 84 5 86 5 88 2 89 3

Esbriet 44 -4 42 -2 46 13 47 -7 55 17

Ocrevus - - - - - - 1 - 3 -

Tarceva 39 -25 37 -22 36 -15 33 -27 34 -18

Pulmozyme 31 6 32 10 30 2 29 -6 33 1

CellCept 44 -4 43 3 45 -1 43 -2 47 -1

Tamiflu 63 * 13 -30 1 -96 1 -88 12 -81

Mircera 22 4 22 3 21 2 21 -12 20 -14

Tecentriq 1 - 2 - 1 * 2 130 12 *

Xeloda 7 -30 6 -28 6 -27 9 5 5 -25

Alecensa 1 * 1 - 4 * 9 * 12 *

Madopar 25 5 23 - 25 0 27 5 28 6

* Over 500%

9

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions



Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016

MabThera/Rituxan 80 11 62 -3 75 5 75 7 81 5

Herceptin 84 7 67 -4 76 -1 73 0 79 -1

Avastin 223 -5 181 -8 209 2 204 5 223 5

Perjeta 31 17 26 7 30 14 30 22 34 15


Xolair - - - - - - - - - -

Lucentis - - - - - - - - - -

Activase/TNKase - - - - - - - - - -

Kadcyla 20 4 16 -9 17 -12 18 2 19 6

Esbriet - - - - - - - - - -

Ocrevus - - - - - - - - - -

Tarceva 28 4 22 -4 24 -10 22 -9 24 -11

Pulmozyme - - - - - - - - - -

CellCept 20 14 17 9 19 13 20 14 22 14

Tamiflu 46 243 65 5 7 183 16 63 60 36

Mircera 63 3 43 -6 54 0 54 3 59 -1

Tecentriq - - - - - - - - - -

Xeloda 29 4 25 -3 27 -4 26 -1 29 5

Alecensa 33 -55 29 50 36 35 38 44 44 39

Madopar 4 -5 4 -2 4 -3 3 1 5 2

10

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions



Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016

MabThera/Rituxan 308 3 327 4 331 10 305 1 309 0

Herceptin 476 1 487 0 491 2 467 0 454 -5

Avastin 304 13 292 7 326 15 273 -5 310 1

Perjeta 59 50 65 47 71 41 72 35 88 45


Xolair - - - - - - - - - -

Lucentis - - - - - - - - - -

Activase/TNKase 12 -10 11 0 12 11 14 16 14 5

Kadcyla 36 38 33 49 36 44 39 53 46 29

Esbriet 3 -43 7 10 9 62 10 113 13 263

Ocrevus - - - - - - 1 - 4 -

Tarceva 44 -11 43 -18 44 -15 30 -19 37 -19

Pulmozyme 25 17 18 3 23 -17 30 50 29 15

CellCept 80 -4 77 -11 78 2 79 4 87 9

Tamiflu 41 20 36 -4 54 222 7 -29 24 -45

Mircera 52 70 50 -5 46 -7 53 -2 62 16

Tecentriq 1 - 2 - 3 - 4 ** 5 300

Xeloda 68 -16 67 -8 71 1 71 -1 75 11

Alecensa - - 2 - 3 - 4 - 7 -

Madopar 47 7 59 30 48 18 51 13 57 20

* Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

** Over 500%

11

10. Roche Group consolidated income statement for the twelve months ended 31 December 2017

in millions of CHF Pharma-

ceuticals Diagnostics Corporate Group

Sales 41,220 12,079 - 53,299

Royalties and other operating income 2,284 163 - 2,447

Cost of sales (11,978) (6,201) - (18,179)

Marketing and distribution (6,960) (2,887) - (9,847)

Research and development (9,704) (1,588) - (11,292)

General and administration (1,620) (1,262) (543) (3,425)

Operating profit 13,242 304 (543) 13,003

Financing costs (839)

Other financial income (expense) 84

Profit before taxes 12,248

Income taxes (3,423)

Net income 8,825

Attributable to

- Roche shareholders 8,633

- Non-controlling interests 192

Earnings per share and non-voting equity security

Basic (CHF) 10.12

Diluted (CHF) 10.04

12

11. Roche Group core results reconciliation – Full Year 2017

in millions of CHF

IFR

S

Glo

bal

res

tru

ctu

rin

g

Inta

ngi

ble

s

amo

rtis

atio

n

Inta

ngi

ble

s

imp

airm

ent

All

ian

ces

& b

usi

nes

s

com

bin

atio

ns

Leg

al &

envi

ron

men

tal

Pen

sio

n p

lan

sett

lem

ents

Glo

bal

iss

ues

No

rmal

isat

ion

of

EC

P t

ax b

enef

it

Co

re

Sales 53,299 - - - - - - - - 53,299

Royalties and other operating income 2,447 - - - - - - - - 2,447

Cost of sales (18,179) 484 1,545 1,784 - - - - - (14,366)

Marketing and distribution (9,847) 326 9 - - - - - - (9,512)

Research and development (11,292) 87 137 676 - - - - - (10,392)

General and administration (3,425) 311 - 1,058 (350) (80) 22 - - (2,464)

Operating profit 13,003 1,208 1,691 3,518 (350) (80) 22 - - 19,012

Financing costs (839) 2 - - 14 4 - - - (819)

Other financial income (expense) 84 - - - (9) - - - - 75

Profit before taxes 12,248 1,210 1,691 3,518 (345) (76) 22 - - 18,268

Income taxes (3,423) (248) (513) (867) (2) 46 (4) 116 31 (4,864)

Net income 8,825 962 1,178 2,651 (347) (30) 18 116 31 13,404

Attributable to

- Roche shareholders 8,633 962 1,162 2,645 (347) (28) 18 116 31 13,192

- Non-controlling interests 192 - 16 6 - (2) - - - 212

EPS - diluted (CHF) 10.04 1.12 1.35 3.07 (0.40) (0.03) 0.02 0.13 0.04 15.34

13

12. Divisional core results reconciliation – Full Year 2017

in millions of

CHF

IFR

S

Glo

bal

res

tru

ctu

rin

g

Inta

ngi

ble

s

amo

rtis

atio

n

Inta

ngi

ble

s

imp

airm

ent

All

ian

ces

& b

usi

nes

s

com

bin

atio

ns

Leg

al &

envi

ron

men

tal

Pen

sio

n p

lan

sett

lem

ents

Co

re

Pharmaceuticals

Sales 41,220 - - - - - - 41,220

Royalties and

other operating

income

2,284 - - - - - - 2,284

Cost of sales (11,978) 377 1,230 1,664 - - - (8,707)

Marketing and

distribution (6,960) 234 6 - - - - (6,720)

Research and

development (9,704) 21 123 524 - - - (9,036)

General and

administration (1,620) 245 - 384 (324) (143) 18 (1,440)

Operating

profit 13,242 877 1,359 2,572 (324) (143) 18 17,601

Diagnostics

Sales 12,079 - - - - - - 12,079

Royalties and

other operating

income

163 - - - - - - 163

Cost of sales (6,201) 107 315 120 - - - (5,659)

Marketing and

distribution (2,887) 92 3 - - - - (2,792)

Research and

development (1,588) 66 14 152 - - - (1,356)

General and

administration (1,262) 27 - 674 (27) 58 4 (526)

Operating

profit 304 292 332 946 (27) 58 4 1,909

Corporate

General and

administration (543) 39 - - 1 5 - (498)

Operating

profit (543) 39 - - 1 5 - (498)

14

13. Roche Group consolidated balance sheet

in millions of CHF 31 December

2017

31 December

2016

Non-current assets

Property, plant and equipment 20,912 19,957

Goodwill 10,077 11,282

Intangible assets 8,368 12,046

Deferred tax assets 3,576 2,826

Defined benefit plan assets 801 738

Other non-current assets 1,370 1,300

Total non-current assets 45,104 48,149

Current assets

Inventories 7,407 7,928

Accounts receivable 9,577 8,760

Current income tax assets 348 335

Other current assets 2,243 2,540

Marketable securities 7,278 4,944

Cash and cash equivalents 4,719 4,163

Total current assets 31,572 28,670

Total assets 76,676 76,819

Non-current liabilities

Long-term debt (15,839) (16,992)

Net deferred tax liabilities (495) (838)

Defined benefit plan liabilities (7,421) (7,678)

Provisions (1,548) (1,777)

Other non-current liabilities (206) (532)

Total non-current liabilities (25,509) (27,817)

Current liabilities

Short-term debt (3,121) (5,363)

Current income tax liabilities (3,408) (2,713)

Provisions (2,042) (2,271)

Accounts payable (3,454) (3,375)

Other current liabilities (10,135) (8,878)

Total current liabilities (22,160) (22,600)

Total liabilities (47,669) (50,417)

Total net assets 29,007 26,402

Equity

Capital and reserves attributable to Roche

shareholders 26,441 23,911

Equity attributable to non-controlling interests 2,566 2,491

Total equity 29,007 26,402

15

14. Roche Group consolidated statement of cash flows

in millions of CHF

FY 2017 FY 2016

Cash flows from operating activities

Cash generated from operations 22,256 21,225

(Increase) decrease in net working capital 427 (1,023)

Payments made for defined benefit plans (538) (880)

Utilisation of provisions (621) (762)

Disposal of products 410 179

Other operating cash flows (1) -

Cash flows from operating activities, before income taxes paid 21,933 18,739

Income taxes paid (3,909) (3,738)

Total cash flows from operating activities 18,024 15,001

Cash flows from investing activities

Purchase of property, plant and equipment (3,509) (4,144)

Purchase of intangible assets (704) (1,001)

Disposal of property, plant and equipment 100 151

Disposal of intangible assets - -

Business combinations (280) (74)

Divestment of subsidiaries 11 -

Interest and dividends received 30 24

Sales of marketable securities 762 597

Purchases of marketable securities (319) (631)

Sales (purchases) of money market instruments and time accounts over

three months, net (2,612) 683

Other investing cash flows 62 (118)

Total cash flows from investing activities (6,459) (4,513)

Cash flows from financing activities

Proceeds from issue of bonds and notes 1,502 3,158

Redemption and repurchase of bonds and notes (3,068) (3,985)

Increase (decrease) in commercial paper (1,258) (454)

Increase (decrease) in other debt (385) (133)

Hedging and collateral arrangements 235 (211)

Changes in non-controlling interests - -

Equity contribution by non-controlling interests - capital injection 5 -

Interest paid (648) (849)

Dividends paid (7,140) (7,040)

Equity-settled equity compensation plans, net of transactions in own

equity (358) (557)

Other financing cash flows - -

Total cash flows from financing activities (11,115) (10,071)

Net effect of currency translation on cash and cash equivalents 106 15

Increase (decrease) in cash and cash equivalents 556 432

Cash and cash equivalents at beginning of period 4,163 3,731

Cash and cash equivalents at end of period 4,719 4,163

full year results 2017: tables - roche - doing now what ...29d4dcde-3b4d-43e3-91d6-08fdbd951… ·...

Documents